Tekne Awards honor key leaders and innovators in Minnesota technology industries

Minnetonka, MN, November 12, 2004 - Medisyn Technologies, a pioneer in rapid drug design, was named the recipient of the Emerging Biotechnology category at the 2004 Tekne Awards held at the Minneapolis Convention Center on November 9. The Tekne Awards recognize Minnesota’s outstanding technology achievements and leaders. "We are thrilled and honored to have earned a Tekne Award," said David Land, President, Medisyn Technologies. "Tekne is the premier technology event in Minnesota, so receiving this kind of business community recognition is incredibly motivating for the Medisyn team and the many company supporters." 

Sponsored jointly by The Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc. (MTI) – and in partnership with Medical Alley, MNBIO and Minnesota Project Innovation – the Tekne Awards recognize technology innovators and leaders who have made lasting contributions to enhancing the quality of life and competitiveness of Minnesota. 

“Earning a Tekne Award is a strong indicator of achievement and leadership in Minnesota’s competitive technology sectors,” said Dr. Wayne Pletcher, president & CEO, Minnesota Technology, Inc. “We’re very proud to honor homegrown successes like Medisyn, because its efforts help strengthen our entire industry, adding to the success of our business environment and our state’s economy.” 

This year’s Tekne Awards were emceed by WCCO television anchor Don Shelby. “Since we first started this program five years ago, it has grown to become a respected honor for our state’s technology innovators and leaders,” said Kate Rubin, president, Minnesota High Tech Association. “All of our 2004 Tekne Award recipients and finalists are living proof of the vital, thriving technology climate here in Minnesota.” 

Tekne Awards are separated into emerging and established company categories recognizing the best and brightest in innovation, development, education, commercialization and management of technology in Minnesota. This year’s awards featured 51 finalists in 17 categories. A list of all recipients and finalists is available online at www.tekneawards.org. 

About Minnesota High Tech Association (MHTA) 
The Minnesota High Tech Association (MHTA) accelerates the growth, success and sustainability of Minnesota's technology-based economy through public policy advocacy, member collaboration and education, and community outreach. MHTA is the only membership organization that represents Minnesota’s entire technology-based economy. MHTA members include organizations of every size − involved in virtually every aspect of technology creation, production, application and education in Minnesota. MHTA works in partnership with AeA, which represents Minnesota's technology organizations nationally. Find out more online at www.mhta.org. 

About Minnesota Technology Inc. (MTI) 
Minnesota Technology Inc. (MTI) is a non-profit, 501(c)3 organization with the mission of helping its business customers gain competitive advantages, supporting their growth, and contributing to Minnesota’s economic vitality. MTI fulfills this work through a statewide staff of expert professionals who have tested expertise across a wide variety of business, technology, manufacturing, engineering, publishing and research disciplines. Over the last three years, MTI has helped nearly 2,000 Minnesota companies and made a significant economic impact. It helped create and retain over 2,500 jobs, saved its clients more than $70 million, and helped generate $80 million in new technology investments. For more information visit www.minnesotatechnology.org. 

About Medisyn Technologies
Medisyn Technologies is a unique drug design and discovery company that uses proprietary technology to make drug discovery faster, more predictable and less expensive. Based on molecular topology, Medisyn’s Forward EngineeringTM platform enables the discovery and design of novel, diverse and unexpected compounds that meet exact parameters for a specific therapeutic use. By compressing design and discovery time from years to weeks and optimizing lead candidates, Medisyn’s novel approach enables drug discovery customers to reduce risk, improve probability of success and control costs associated with the traditional lead discovery process. The company is initially focused on treating cancer and is currently completing pre-clinical validation of MT103, a promising lead candidate for non-small cell lung cancer. It has an additional 26 anti-cancer compounds in varying stages of development. Medisyn Technologies is headquartered in Minneapolis, MN. For more information about Medisyn Technologies, visit the company’s website at: www.medisyntech.com or call 952.475.8084. 

Pam Pettinella